Analysts’ updated eps estimates for Thursday, September 7th:
Apple (NASDAQ:AAPL) had its buy rating reissued by analysts at Drexel Hamilton. The firm currently has a $208.00 price target on the stock. The analysts wrote, “We continue to believe Apple’s stock will not only benefit from the upcoming iPhone cycle but also the company’s capital distribution initiative, attractive valuation and potential new innovations. As such, we do not believe Apple’s run will end with next week’s iPhone event but still has attractive upside potential as we are projecting with our $208 price target. Preliminary August sales (96% of sales have been reported) for our Apple Monitor rose by 14-15% MoM, better than the average increase of 8% over the past twelve years. This compares to the five-year average of up 10%. Moreover, this August performance is much better than the 5% MoM increase in August 2014 when the iPhone 6 Plus experienced yield issues.””
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its overweight rating reiterated by analysts at Barclays PLC. The firm currently has a $105.00 price target on the stock, up from their previous price target of $80.00.
Expedia (NASDAQ:EXPE) had its hold rating reissued by analysts at Stifel Nicolaus. They currently have a $160.00 price target on the stock. The analysts wrote, “We are adjusting our Expedia model to incorporate reduced trivago forecasts and our PT remains $160. Key Points Trivago reduces full year guidance: Trivago reduced its revenue growth guidance for FY:17 to 40% y/y, from 50% y/y previously, implying 2H:17 revenue ~18% lower than previously expected. Adj. EBITDA is now expected to be lower y/y but remain positive, versus guidance previously calling for a slightly improved EBITDA margin. Trivago attributed revenue growth headwinds primarily to a greater-than-anticipated pricing impact from the unwinding of its relevance assessment program, which launched at the end of 2016. The relevance assessment program required advertisers with lower relevance scores to place higher bids in the auction system to drive equivalent volume to their sites.””
Cedar Fair, L.P. (NYSE:FUN) had its buy rating reiterated by analysts at FBR & Co.
Navistar International Corporation (NYSE:NAV) had its positive rating reiterated by analysts at Jefferies Group LLC. They currently have a $47.00 target price on the stock.
National Retail Properties (NYSE:NNN) had its buy rating reaffirmed by analysts at FBR & Co. The firm currently has a $52.00 target price on the stock. The analysts wrote, “NNN priced an underwritten public offering of $400 million of 3.5% senior notes due 2027. The company intends to use the net proceeds to repay all of the outstanding indebtedness under its credit facility, with the remainder going towards property acquisitions and other general purposes. We assume the company will use the proceeds partially to pay down its line of credit as well as pay off its 6.875% unsecured notes in October 2017.””
Vericel Corporation (NASDAQ:VCEL) had its buy rating reissued by analysts at BTIG Research. The firm currently has a $6.00 price target on the stock. The analysts wrote, “Among Cartilage Repair Surgeons We had the opportunity to host a key opinion leader (KOL) call with Dr. James Carey, MD, MPH, Director of University of Pennsylvania’s Center for Cartilage Repair and Osteochondritis Dissecans Treatment. Dr. Carey is well positioned to opine on the topic of cartilage repair as he has given more than 60 presentations on the topic and authored more than 50 papers in the area of cartilage repair. Dr. Carey also conducts some of the highest ACI repair volume in the US. Our high level takeaways from the call support our view that MACI offers physicians and patients lifestyle benefits including faster operative times, ease of placement, and patient convenience in scheduling the procedure.””
Western Digital Corporation (NASDAQ:WDC) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $135.00 target price on the stock.
Zpg Plc (LON:ZPG) had its add rating reissued by analysts at Peel Hunt. They currently have a GBX 390 ($5.04) target price on the stock.
Zymeworks (NASDAQ:ZYME) had its sell rating reissued by analysts at Barclays PLC. Barclays PLC currently has a $8.00 price target on the stock.
